Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?

Most patients with non‐small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations, such as deletions in exon 19 or the L858R mutation in exon 21, respond dramatically to EGFR tyrosine kinase inhibitors (EGFR‐TKI), and their sensitivities to various EGFR‐TKI hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Banno, Eri, Togashi, Yosuke, Nakamura, Yu, Chiba, Masato, Kobayashi, Yoshihisa, Hayashi, Hidetoshi, Terashima, Masato, de Velasco, Marco A., Sakai, Kazuko, Fujita, Yoshihiko, Mitsudomi, Tetsuya, Nishio, Kazuto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982590/
https://www.ncbi.nlm.nih.gov/pubmed/27240419
http://dx.doi.org/10.1111/cas.12980

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982590/
https://www.ncbi.nlm.nih.gov/pubmed/27240419
http://dx.doi.org/10.1111/cas.12980

Ejemplares similares